youtube_live
Q3 2026 earnings • 8:00 AM tomorrow
See detailschevron_right
MDGL:NASDAQ
Madrigal Pharmaceuticals Inc
$431.16
arrow_upward
+0.18%(+0.80) 1D
$431.16
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 2, 4:00:01 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MDGL...
Open
$430.04
High
$436.74
Low
$425.33
Mkt. cap
9.96B
Avg. vol.
282.29K
Volume
495.14K
52-wk high
$615.00
52-wk low
$399.00
EPS
-$12.87
Beta
-1.04
Shares outstanding
23.10M
No. of employees
915
Open
$430.04
High
$436.74
Low
$425.33
Mkt. cap
9.96B
Avg. vol.
282.29K
Volume
495.14K
52-wk high
$615.00
52-wk low
$399.00
EPS
-$12.87
Beta
-1.04
Shares outstanding
23.10M
No. of employees
915
News stories
From web sources and news partners
Investing.com
·
10 hours ago
Madrigal Pharmaceuticals earnings on deck as MASH sales test continues
About Madrigal Pharmaceuticals Inc
CEOPaul A. Friedman
Employees915
Founded2011
HeadquartersWest Conshohocken, Pennsylvania, United States
SectorBiotechnology
Websitemadrigalpharma.com
Analyst ratings
Based on 10 analysts giving stock ratings to MDGL in the past 3 months
Strong buy
Buy
9
Hold
1
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for MDGL in the last 3 months.
Highest
Current $431.16
$962.00 (+123.12%)
Average
$685.10 (+58.90%)
Lowest
$533.00 (+23.62%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Unknown Analyst B. Riley Securities | Buy | Reiterated | $670.00 | +55.4% | 10/29/2026 |
Edward Nash Canaccord Genuity | Buy | Maintained | $612.00 | +41.9% | 10/29/2026 |
Jason Zemansky Bank of America Securities | Hold | Reiterated | $533.00 | +23.6% | 10/19/2026 |
Sadia Rahman Wells Fargo | Buy | Maintained | $685.00 | +58.9% | 10/16/2026 |
Ashwani Verma UBS | Buy | Maintained | $735.00 | +70.5% | 10/15/2026 |
Andrew Fein H.C. Wainwright | Buy | Reiterated | $620.00 | +43.8% | 10/08/2026 |
Eliana Merle Barclays | Buy | Maintained | $962.00 | +123.1% | 09/30/2026 |
Andrea Newkirk Goldman Sachs | Buy | Initiated | $704.00 | +63.3% | 09/24/2026 |
Eric Joseph Citi | Buy | Initiated | $725.00 | +68.2% | 09/23/2026 |
Andy Chen Wolfe Research | Buy | Upgraded | $605.00 | +40.3% | 08/04/2026 |
Srikripa Devarakonda Truist Financial | Buy | Reiterated | $709.00 | +64.4% | 07/31/2026 |
Ritu Baral TD Cowen | Buy | Maintained | $644.00 | +49.4% | 07/30/2026 |
Unknown Analyst UBS | Buy | Maintained | $669.00 | +55.2% | 07/21/2026 |
Jonathan Wolleben Citizens JMP | Buy | Maintained | $739.00 | +71.4% | 07/17/2026 |
Unknown Analyst Jefferies | Buy | Maintained | $600.00 | +39.2% | 06/30/2026 |
Yasmeen Rahimi Piper Sandler | Buy | Maintained | $900.00 | +108.7% | 06/29/2026 |
Michael DiFiore Evercore ISI | Buy | Maintained | $649.00 | +50.5% | 05/07/2026 |
Kaveri Pohlman Clear Street | Buy | Maintained | $680.00 | +57.7% | 05/06/2026 |
Jay Olson Oppenheimer | Buy | Maintained | $650.00 | +50.8% | 02/09/2026 |
Next call in 10:57:31
Tomorrow, 8:00 AM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / -$1.09
Revenue / Est. (USD)
- / 405.12M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 287.27M | 321.08M | 311.34M | 364.25M |
Cost of goods sold | 18.12M | 24.45M | 26.85M | 40.01M |
Cost of revenue | 18.12M | 24.45M | 26.85M | 40.01M |
Research and development expenses | 174.00M | 116.27M | 108.69M | 91.18M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 209.12M | 239.98M | 268.52M | 289.38M |
Operating expense | 383.12M | 356.24M | 377.21M | 380.55M |
Total operating expenses | 401.24M | 380.69M | 404.06M | 420.56M |
Operating income | -113.98M | -59.61M | -92.72M | -56.31M |
Other non operating income | -293.00K | -128.00K | - | - |
EBT including unusual items | -114.19M | -58.58M | -94.39M | -57.94M |
EBT excluding unusual items | -111.41M | -58.58M | -94.39M | -57.94M |
Income tax expense | - | - | - | - |
Effective tax rate | - | - | - | - |
Other operating expenses | - | - | - | - |
Net income | -114.19M | -58.58M | -94.39M | -57.94M |
Net profit margin | -39.75% | -18.24% | -30.32% | -15.91% |
Earnings per share | -4.96 | -2.57 | -1.38 | -1.99 |
Interest and investment income | 10.31M | 9.46M | 8.24M | 7.10M |
Interest expense | -7.45M | -8.30M | -7.82M | -7.94M |
Net interest expenses | 2.86M | 1.16M | 424.00K | -836.00K |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -113.62M | -59.22M | -92.34M | -55.93M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events